|Do circulating tumor cells play a role in coagulation and thrombosis?|
|Jump to Full Text|
|PMID: 22973557 Owner: NLM Status: PubMed-not-MEDLINE|
|Cancer induces a hypercoagulable state, and patients with cancer who suffer a thrombotic event have a worse prognosis than those who do not. Recurrent pathologic thrombi in patients with cancer are clinically managed with anticoagulant medications; however, anticoagulant prophylaxis is not routinely prescribed owing to a complex variety of patient and diagnosis related factors. Early identification of patients at risk for cancer-associated thrombosis would allow for personalization of anticoagulant prophylaxis and likely reduce morbidity and mortality for many cancers. The environment in which a thrombosis develops in a patient with cancer is complex and unique from patients without cancer, which creates therapeutic challenges but may also provide targets for the development of clinical assays in this context. Circulating tumor cells (CTCs) may play a role in the association between cancer and thrombosis. Cancer metastasis, the leading cause of cancer-related deaths, is facilitated by the hematogenous spread of CTCs, and CTCs accompany metastatic disease across all major types of carcinomas. The role of CTCs in the pathogenesis of thrombosis has not been studied due to the previous difficulty in identifying these rare cells, but the interaction between these circulating cells and the coagulation system is an area of study that demands attention. The development of CTC detection platforms presents a new tool by which to characterize the role for CTCs in cancer-related hypercoagulability. In addition, this area of study presents a new avenue for assessing the risk of cancer-associated thrombosis and represents a potential tool for predicting which patients may benefit from anticoagulant prophylaxis. In this review, we will discuss the evidence in support of CTC induced hypercoagulability, and highlight areas where CTC-detection platforms may provide prognostic insight into the risk of developing thrombosis for patients with cancer.|
|Garth W Tormoen; Kristina M Haley; Ross L Levine; Owen J T McCarty|
Related Documents :
|16555127 - Effect of vinca alkaloids on eralpha levels and estradiol-induced responses in mcf-7 ce...
23516577 - P38/nf-κb/snail pathway is involved in caffeic acid-induced inhibition of cancer stem ...
17627567 - The endothelin axis: a novel target for pharmacotherapy of female malignancies.
23366417 - Roles of bioactive sphingolipid metabolites in ovarian cancer cell biomechanics.
16433197 - The emerging role of oxaliplatin in the treatment of gastric cancer.
22235157 - Needs and experiences of samoan breast cancer survivors in southern california.
|Type: Journal Article Date: 2012-09-10|
|Title: Frontiers in oncology Volume: 2 ISSN: 2234-943X ISO Abbreviation: Front Oncol Publication Date: 2012|
|Created Date: 2012-09-13 Completed Date: 2012-09-14 Revised Date: 2013-08-13|
Medline Journal Info:
|Nlm Unique ID: 101568867 Medline TA: Front Oncol Country: Switzerland|
|Languages: eng Pagination: 115 Citation Subset: -|
|Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University Portland, OR, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Journal ID (nlm-ta): Front Oncol
Journal ID (iso-abbrev): Front Oncol
Journal ID (publisher-id): Front. Oncol.
Publisher: Frontiers Research Foundation
Copyright © Tormoen, Haley, Levine and McCarty
Received Day: 01 Month: 6 Year: 2012
Accepted Day: 23 Month: 8 Year: 2012
Electronic publication date: Day: 10 Month: 9 Year: 2012
collection publication date: Year: 2012
Volume: 2E-location ID: 115
PubMed Id: 22973557
|Do circulating tumor cells play a role in coagulation and thrombosis?|
|Garth W. Tormoen1*|
|Kristina M. Haley2|
|Ross L. Levine3|
|Owen J. T. McCarty14|
1Department of Biomedical Engineering, School of Medicine, Oregon Health & Science UniversityPortland, OR, USA
2Division of Pediatric Hematology/Oncology, Department of Pediatrics, Oregon Health & Science UniversityPortland, OR, USA
3Human Oncology and Pathogenesis Program, Memorial Sloan–Kettering Cancer CenterNew York, NY, USA
4Department of Cell & Developmental Biology, School of Medicine, Oregon Health & Science UniversityPortland, OR, USA
|[edited-by] Edited by: Michael R. King, Cornell University, USA
[edited-by] Reviewed by: Soldano Ferrone, University of Pittsburgh Cancer Institute, USA; Massimiliano Agostini, Medical Research Council, UK; Tara L. Beattie, University of Calgary, Canada
Correspondence: *Correspondence: Garth W. Tormoen, Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, 3303 South West Bond Avenue, Portland, OR 97239, USA. e-mail: email@example.com
[other] This article was submitted to Frontiers in Cancer Molecular Targets and Therapeutics, a specialty of Frontiers in Oncology.
Cancer is a hypercoagulable state, and the association of venous thrombosis with cancer has been observed for centuries (Trousseau, 1865). Thrombosis is a significant contributor to morbidity and mortality in cancer patients. Patients with cancer who suffer a thrombosis as a part of their disease endure worse outcomes (Sorensen et al., 2000). Despite the well established link between cancer and venous thrombosis, anticoagulation is not routine care for these patients (Akl et al., 2011a,b). This is due in part to the increased bleeding risk associated with anticoagulation in a population where only a fraction of patients develop symptomatic thrombosis, and the risks of anticoagulation therapy in patients treated with systemic chemotherapy and with disease and/or therapy related thrombocytopenia. No clinical marker has been developed which is capable of predicting in which patients the benefit of anticoagulation outweighs the increased risk of bleeding.
The underlying cause of thrombosis in cancer is multifactorial, including but not limited to, personal and family history of thrombosis, pre-treatment fibrinogen and platelet levels, immobility and fatigue, the increased use of indwelling catheters, and the administration of certain chemotherapeutics and other anticancer therapies which increase thrombotic risk (Dimopoulos and Eleutherakis-Papaiakovou, 2004; Elice et al., 2009). However, thrombosis can also herald the diagnosis of cancer, preceding any cancer-related symptoms or treatments. This, in itself, underlines the role for cancer in disrupting the normal physiological balance of the hemostatic system. The incidence of thrombosis in cancer is strongly tied to cancer subtype and origin, suggesting that cancer cells directly contribute to the hypercoagulable state associated with cancer (i.e., adenocarcinoma vs. carcinoma or colon vs. breast; Baron et al., 1998; Sorensen et al., 1998; Rickles and Levine, 2001; Blom et al., 2004). A multifactorial model to estimate risk of thrombosis in patients receiving chemotherapy has been validated which includes the cancer site, factors such as platelet and leukocyte count, and hemoglobin level or the use of erythropoiesis-stimulating agents, and body mass index to stratify patients by risk to develop thrombosis. However, the majority of patients predicted to have the highest risk of developing thrombosis in this model do not subsequently suffer from thrombosis (Khorana et al., 2008). Therefore, efforts to identify patients with cancer who will develop venous thrombosis need to achieve better specificity by including additional factors, such as circulating tumor cell (CTC) count, which may have a role in developing cancer-related thrombosis.
Tissue factor (TF) is the physiological initiator of coagulation and is essential for hemostasis. TF is a transmembrane glycoprotein and requires phospholipids in order to be procoagulant (Nemerson, 1968). TF-expressing cells are not typically exposed to the blood. Only upon injury, when the architecture of the blood vessel is disrupted, does the blood gain exposure to extravascular TF-expressing cells. Therefore, in hemostasis, the activation of coagulation is essentially localized to sites of hemorrhage.
In the context of metastatic cancer, CTCs intravasate into the vasculature in order to reach distant locations and establish metastatic foci. CTCs accompany metastatic disease across all major types of carcinomas (Allard et al., 2004). Tumors have been shown to express TF in vivo, and TF expression has been shown to correlate with metastatic potential (Zacharski et al., 1983, 1986; Lee et al., 2011; Liu et al., 2011; Ma et al., 2011; Tian et al., 2011; Xu et al., 2011; Gil-Bernabe et al., 2012). Therefore, the process of hematogenous metastasis may present TF-expressing tumor cells to blood in the absence of a blood vessel injury. Whether metastasizing cancer cells are involved in the development of thrombosis has not been established. In vitro, cancer cells added to blood or plasma promote coagulation in a TF- and phosphatidylserine (PS)-dependent manner, and the coagulation kinetics are strongly dependent upon the number of cancer cells tested (Berny-Lang et al., 2011; Tormoen et al., 2011; Yates et al., 2011; Welsh et al., 2012). However, extrapolation of in vitro coagulation assays to in vivo phenomenon is not straightforward. Cancer cell lines may not reproduce CTC procoagulant phenotypes, and extrapolation of in vitro coagulation kinetics to physiological scenarios is complicated by dynamic physiological environments seen in vivo. Along these lines, blood flow is a strong determinant of procoagulant activity (Gemmell et al., 1988), yet a metastasizing cancer cell has dynamic temporal and spatial relationships with the blood which are unique from TF-bearing cells exposed at the site of a blood vessel injury. For instance, an intravasating or extravasating tumor cell is stationary relative to the blood flow, and thereby would experience rapid changes in coagulation kinetics due to the blood flow-mediated transport of coagulation factors to the stationary cell. In contrast, CTCs in the bloodstream experience very little relative blood flow, as these cells are transported by viscous forces within the flowing blood. The resulting coagulation kinetics for CTCs is therefore reliant upon diffusion of coagulation factors to/from the cell surface; thus the coagulation kinetics for CTCs is diffusion-limited.
The extent to which spatial and temporal relationships affect procoagulant activity of CTCs is a topic of recent investigation. In this issue, Lee et al. (2011) model the generation and coalescence of thrombin by procoagulant CTCs within the circulation and predict local thrombin concentration gradients surrounding the CTCs to have complex relationships with cell counts and distributions within the vasculature. This work suggests that procoagulant CTC counts strongly determine local thrombin concentrations, which would likely be prognostic for risk of developing thrombosis.
Cell-mediated coagulation requires the binding of coagulation factors from solution, followed by the assembly of enzyme complexes on the cell surface. This assembly is facilitated by the exposure of PS. The exposure of PS and subsequent assembly of enzyme complexes on the cell surface may be rate-limiting for the cell’s procoagulant activity. In vitro, the procoagulant activity of several cancer cell lines has been shown to correlate with the extent of PS exposure, more so than the relative expression of TF, supporting the notion that facilitation of enzyme complex assembly is the rate determining mechanism for cancer cell-mediated coagulation (Barrowcliffe et al., 2002; Pickering et al., 2004). Further, space limitations of the PS-regions can severely reduce coagulation kinetics, indicating a role for quantification of procoagulant surface area to assess the procoagulant activity of a cell (Haynes et al., 2012). This limitation suggests that the procoagulant phenotype of CTCs may be dependent upon the physical parameters (size and surface area) of CTCs. In this issue, Phillips et al. (2012a,b) demonstrate methods to utilize light microscopy to quantify the physical parameters of volume, mass, surface area, and density of CTCs, providing a novel technique to assess CTC heterogeneity in cancer-associated hypercoagulability.
Characterizing the role for procoagulant CTCs to initiate coagulation requires a method to functionally probe the ability of CTC to mediate coagulation. Surface expression of TF could be determined through immunofluorescent labeling methods, but these approaches do not capture the activity of TF. The ability of TF to initiate coagulation is dependent upon the cell membrane environment, specifically the exposure of PS, as well as an “active” or “decrypted” form of TF in order to facilitate coagulation. In this issue, Tormoen et al. (2012) describe an approach utilizing fluorescently labeled coagulation factors to characterize the procoagulant nature of CTCs. This approach has potential to functionally characterize the ability of CTCs to bind coagulation factors, which is crucial for their ability to facilitate coagulation. This functional labeling lends itself to current CTC detection platforms (Krivacic et al., 2004; Hsieh et al., 2006), providing a novel method with which CTC platforms can provide novel insight into cancer-related thrombosis.
It has been shown that platelets, the primary mediators of hemostasis, play a key a role in mediating hematogenous metastasis (Gasic et al., 1968, 1973). In vitro, tumor cells bind platelets under shear stress (McCarty et al., 2000, 2002) and cause platelet aggregation, and this ability correlates with metastatic potential in vivo (Karpatkin et al., 1988; Amirkhosravi et al., 2003; Palumbo et al., 2005; Erpenbeck et al., 2010). The mechanisms by which platelet interactions confer metastatic potential upon CTCs are complex. Platelets can deter NK cell destruction of CTCs in the blood (Karpatkin et al., 1988; Im et al., 2004; Kopp et al., 2009). Releasates from activated platelets include growth factors such as platelet-derived growth factor, vascular endothelial growth factor, and transforming growth factor beta, and may support tumor growth and may promote the establishment of metastatic tumor sites (Kepner and Lipton, 1981; Assoian et al., 1983; Mohle et al., 1997; Nierodzik and Karpatkin, 2006). Recently, a murine model of superficial venous thrombophlebitis, a specific clinical presentation of thrombosis that can be associated with mucinous tumors, was shown to depend upon platelet activation (Shao et al., 2011). However, the role for platelet–CTC interactions for venous thrombosis has not been established in different cancer-related contexts.
While the extreme rarity of CTCs in human solid tumors has prevented their characterization, leukemias, which are composed of circulating cancer cells, or “liquid tumors,” supply vast numbers of cancer cells to the bloodstream, making their isolation straightforward. Thrombosis is commonly seen with specific leukemia subtypes, and surface expression of TF has been identified on some leukemic cells associated with coagulopathy (De Stefano et al., 2005; Falanga et al., 2008; Liu et al., 2008; Falanga and Marchetti, 2009; Ku et al., 2009; Musil and Krc, 2010). However, converse to solid tumors and certain leukemia subtypes, hemorrhage is more common in most acute leukemias as compared to thrombosis (Barbui et al., 1998; Barbui and Falanga, 2001; Falanga and Barbui, 2001; Falanga and Rickles, 2003). Suggested mechanisms by which leukemias induce hemorrhage include bone marrow crowding and suppression of platelet production leading to thrombocytopenia. Acute myelogenous leukemia French-American-British subtype M3 or acute promyelocytic leukemia (APL), is known to surface-express TF as well as Annexin II (Menell et al., 1999), and is associated with the highest risk of thrombosis and bleeding amongst all leukemia subtypes. TF activity has been demonstrated from APL cells in vitro, suggesting that these cells are procoagulant. However, rather than developing focal thromboses, patients with APL present with a diffuse coagulopathy that consumes the coagulation factors within the blood leaving the patient unable to maintain hemostasis, resulting in a hemorrhagic phenotype. The surface expression of Annexin II has been shown to correlate with incidence of hemorrhage, and an Annexin II-mediated binding of tissue type plasminogen activator has been demonstrated in vitro (Menell et al., 1999). Therefore, in certain conditions, leukemia cells may initiate and propagate coagulation, while simultaneously facilitating anticoagulation, with the net coagulant effect resulting in consumption of coagulation factors until the patient is severely deficient and deposed toward clinically severe hemorrhage.
Metastasizing CTCs must survive the blood circulation, and the role that blood protein and blood cell interactions with CTCs plays in the progression of metastatic disease in human cancers remains ill-defined. The association between cancer and thrombosis suggests that the circulation is not inert toward CTCs, however the characterization of human CTC and blood interactions has been hampered by the technical difficulty in isolating and analyzing these rare cells. The emergence of clinical CTC detection platforms in recent years has opened the possibility to characterize the role that CTCs play in metastatic disease. One of the challenges facing researchers in this field is how to functionally characterize CTCs within the technical constraints that current CTC detection platforms require. This special edition of Frontiers in Oncology describes several methods with which CTCs are biophysically characterized using light microscopy techniques (see Phillips et al., 2012a,b). The development of CTC detection platforms to probe procoagulant properties of these cells presents new opportunities for investigators to understand the relationship between CTCs and blood proteins and/or blood cells. This theme is explored in Tormoen et al. (2012). Finally, understanding the complex environment that CTCs within the blood circulation traverse, and the effects that this environment has on the procoagulant phenotype of CTCs is addressed in Lee et al. (2012). The therapeutic targeting of CTCs may provide new insight into metastatic disease, including methods to interrogate the procoagulant nature of CTCs and understand how these relationships impact cancer progression and cancer-related morbidities and the response to antithrombotic therapies.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This research was supported in part by the OHSU Knight Cancer Institute (Owen J. T. McCarty), the American Heart Association (12PRE11930019 to Garth W. Tormoen), and the NIH (R01HL101972 and U54CA143906 to Owen J. T. McCarty, U54CA143798 to Ross L. Levine, T32-CA106195 to Garth W. Tormoen). Kristina M. Haley is a Medical Research Foundation Early Career Investigator. Garth W. Tormoen is an Achievement Rewards for College Scientists scholar.
|Akl E. A.,Labedi N.,Barba M.,Terrenato I.,Sperati F.,Muti P.,Schünemann H.. (Year: 2011a). Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.Cochrane Database Syst. Rev.6CD006650|
|Akl E. A.,Vasireddi S. R.,Gunukula S.,Yosuico V. E.,Barba M.,Terrenato I.,Sperati F.,Schünemann H.. (Year: 2011b). Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation.Cochrane Database Syst. Rev.12CD006466|
|Allard W. J.,Matera J.,Repollet M.,Connelly M. C.,Rao C.,Tibbe A. G.,Uhr J. W.,Terstappen L. W.. (Year: 2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.Clin. Cancer Res.106897–690415501967|
|Amirkhosravi A.,Mousa S. A.,Amaya M.,Blaydes S.,Desai H.,Meyer T.,Francis J. L.. (Year: 2003). Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454.Thromb. Haemost.90549–55412958625|
|Assoian R. K.,Komoriya A.,Meyers C. A.,Miller D. M.,Sporn M. B.. (Year: 1983). Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem.2587155–71606602130|
|Barbui T.,Falanga A.. (Year: 2001). Disseminated intravascular coagulation in acute leukemia.Semin. Thromb. Hemost.27593–60411740683|
|Barbui T.,Finazzi G.,Falanga A.. (Year: 1998). The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia.Blood913093–31029558362|
|Baron J. A.,Gridley G.,Weiderpass E.,Nyrén O.,Linet M.. (Year: 1998). Venous thromboembolism and cancer.Lancet3511077–10809660575|
|Barrowcliffe T. W.,Fabregas P.,Jardi M.,Cancelas J.,Rabaneda M.,Felez J.. (Year: 2002). Procoagulant activity of T lymphoblastoid cells due to exposure of negatively charged phospholipid.Thromb. Haemost.87442–44911916077|
|Berny-Lang M. A.,Aslan J. E.,Tormoen G. W.,Patel I. A.,Bock P. E.,Gruber A.,McCarty O. J.. (Year: 2011). Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells.Phys. Biol.8015014|
|Blom J. W.,Osanto S.,Rosendaal F. R.. (Year: 2004). The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma.J. Thromb. Haemost.21760–176515456487|
|De Stefano V.,Sora F.,Rossi E.,Chiusolo P.,Laurenti L.,Fianchi L.,Zini G.,Pagano L.,Sica S.,Leone G.. (Year: 2005). The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.J. Thromb. Haemost.31985–199216102104|
|Dimopoulos M. A.,Eleutherakis-Papaiakovou V.. (Year: 2004). Adverse effects of thalidomide administration in patients with neoplastic diseases.Am. J. Med.117508–51515464708|
|Elice F.,Rodeghiero F.,Falanga A.,Rickles F. R.. (Year: 2009). Thrombosis associated with angiogenesis inhibitors.Best Pract. Res. Clin. Haematol.22115–12819285278|
|Erpenbeck L.,Nieswandt B.,Schön M.,Pozgajova M.,Schön M. P.. (Year: 2010). Inhibition of platelet GPIb alpha and promotion of melanoma metastasis.J. Invest. Dermatol.130576–58619727118|
|Falanga A.,Barbui T.. (Year: 2001). Coagulopathy of acute promyelocytic leukemia.Acta Haematol.10643–5111549776|
|Falanga A.,Barbui T.,Rickles F. R.. (Year: 2008). Hypercoagulability and tissue factor gene upregulation in hematologic malignancies.Semin. Thromb. Hemost.34204–21018645927|
|Falanga A.,Marchetti M.. (Year: 2009). Venous thromboembolism in the hematologic malignancies.J. Clin. Oncol.274848–485719752334|
|Falanga A.,Rickles F. R.. (Year: 2003). Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia.Best Pract. Res. Clin. Haematol.16463–48212935963|
|Gasic G. J.,Gasic T. B.,Galanti N.,Johnson T.,Murphy S.. (Year: 1973). Platelet–tumor-cell interactions in mice. The role of platelets in the spread of malignant disease.Int. J. Cancer11704–7184801854|
|Gasic G. J.,Gasic T. B.,Stewart C. C.. (Year: 1968). Antimetastatic effects associated with platelet reduction.Proc. Natl. Acad. Sci. U.S.A.6146–525246932|
|Gemmell C. H.,Turitto V. T.,Nemerson Y.. (Year: 1988). Flow as a regulator of the activation of factor X by tissue factor.Blood721404–14063262388|
|Gil-Bernabe A. M.,Ferjancic S.,Tlalka M.,Zhao L.,Allen P. D.,Im J. H.,Watson K.,Hill S. A.,Amirkhosravi A.,Francis J. L.,Pollard J. W.,Ruf W.,Muschel R. J.. (Year: 2012). Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice.Blood1193164–317522327225|
|Haynes L. M.,Dubief Y. C.,Mann K. G.. (Year: 2012). Membrane binding events in the initiation and propagation phases of tissue factor-initiated zymogen activation under flow.J. Biol. Chem.2875225–523422187432|
|Hsieh H. B.,Marrinucci D.,Bethel K.,Curry D. N.,Humphrey M.,Krivacic R. T.,Kroener J.,Kroener L.,Ladanyi A.,Lazarus N.,Kuhn P.,Bruce R. H.,Nieva J.. (Year: 2006). High speed detection of circulating tumor cells.Biosens. Bioelectron.211893–189916464570|
|Im J. H.,Fu W.,Wang H.,Bhatia S. K.,Hammer D. A.,Kowalska M. A.,Muschel R. J.. (Year: 2004). Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation.Cancer Res.648613–861915574768|
|Karpatkin S.,Pearlstein E.,Ambrogio C.,Coller B. S.. (Year: 1988). Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo.J. Clin. Invest.811012–10193280598|
|Kepner N.,Lipton A.. (Year: 1981). A mitogenic factor for transformed fibroblasts from human platelets.Cancer Res.41430–4326256066|
|Khorana A. A.,Kuderer N. M.,Culakova E.,Lyman G. H.,Francis C. W.. (Year: 2008). Development and validation of a predictive model for chemotherapy-associated thrombosis.Blood1114902–490718216292|
|Kopp H. G.,Placke T.,Salih H. R.. (Year: 2009). Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.Cancer Res.697775–778319738039|
|Krivacic R. T.,Ladanyi A.,Curry D. N.,Hsieh H. B.,Kuhn P.,Bergsrud D. E.,Kepros J. F.,Barbera T.,Ho M. Y.,Chen L. B.,Lerner R. A.,Bruce R. H.. (Year: 2004). A rare-cell detector for cancer.Proc. Natl. Acad. Sci. U.S.A.10110501–1050415249663|
|Ku G. H.,White R. H.,Chew H. K.,Harvey D. J.,Zhou H.,Wun T.. (Year: 2009). Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival.Blood1133911–391719088376|
|Lee A.,Tormoen G. W.,Kanso E.,McCarty O. J.,Newton P. K.. (Year: 2012). Modeling and simulation of procoagulant circulating tumor cells in flow.Front. Oncol. 2:108.10.3389/fonc.2012.00108|
|Lee B. J.,Kim J. H.,Woo S. H.,Kim J. H.,Kim D. H.,Yu Y. S.. (Year: 2011). Tissue factor is involved in retinoblastoma cell proliferation via both the Akt and extracellular signal-regulated kinase pathways.Oncol. Rep.26665–67021617868|
|Liu Y.,Chao X.,Gu W.,Hua X.,Xu N.. (Year: 2008). Acute thrombosis in superior mesenteric artery as first symptom in a AML patient.Int. J. Gen. Med.17–920428399|
|Liu Y.,Jiang P.,Capkova K.,Xue D.,Ye L.,Sinha S. C.,Mackman N.,Janda K. D.,Liu C.. (Year: 2011). Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy.Cancer Res.716492–650221880589|
|Ma Z.,Zhang T.,Wang R.,Cheng Z.,Xu H.,Li W.,Wang Y.,Wang X.. (Year: 2011). Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism.Int. J. Gynecol. Cancer21616–62421543928|
|McCarty O. J.,Jadhav S.,Burdick M. M.,Bell W. R.,Konstantopoulos K.. (Year: 2002). Fluid shear regulates the kinetics and molecular mechanisms of activation-dependent platelet binding to colon carcinoma cells.Biophys. J.83836–84812124268|
|McCarty O. J.,Mousa S. A.,Bray P. F.,Konstantopoulos K.. (Year: 2000). Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions.Blood961789–179710961878|
|Menell J. S.,Cesarman G. M.,Jacovina A. T.,McLaughlin M. A.,Lev E. A.,Hajjar K. A.. (Year: 1999). Annexin II and bleeding in acute promyelocytic leukemia.N. Engl. J. Med.340994–100410099141|
|Mohle R.,Green D.,Moore M. A.,Nachman R. L.,Rafii S.. (Year: 1997). Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.Proc. Natl. Acad. Sci. U.S.A.94663–6689012841|
|Musil D.,Krc I.. (Year: 2010). Migrating venous thrombosis in acute leukemia.Blood Coagul. Fibrinolysis21365–36720305540|
|Nemerson Y.. (Year: 1968). The phospholipid requirement of tissue factor in blood coagulation.J. Clin. Invest.4772–8016695947|
|Nierodzik M. L.,Karpatkin S.. (Year: 2006). Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype.Cancer Cell10355–36217097558|
|Palumbo J. S.,Talmage K. E.,Massari J. V.,La Jeunesse C. M.,Flick M. J.,Kombrinck K. W.,Jirousková M.,Degen J. L.. (Year: 2005). Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells.Blood105178–18515367435|
|Phillips K. G.,Kolatkar A.,Rees K. J.,Rigg R.,Marrinucci D.,Luttgen M.,Bethel K.,Kuhn P,McCarty O. J.. (Year: 2012a). Quantification of cellular volume and sub-cellular density fluctuations: comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient.Front. Oncol. 2:96.10.3389/fonc.2012.00096|
|Phillips K. G.,Velasco C. R.,Li J.,Kolatkar A.,Luttgen M.,Bethel K.,Duggan B.,Kuhn P,McCarty O. J.. (Year: 2012b). Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient.Front. Oncol. 2:72.10.3389/fonc.2012.00072|
|Pickering W.,Gray E.,Goodall A. H.,Ran S.,Thorpe P. E.,Barrowcliffe T. W.. (Year: 2004). Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines.J. Thromb. Haemost.2459–46715009464|
|Rickles F. R.,Levine M. N.. (Year: 2001). Epidemiology of thrombosis in cancer.Acta Haematol.1066–1211549771|
|Shao B.,Wahrenbrock M. G.,Yao L.,David T.,Coughlin S. R.,Xia L.,Varki A.,McEver R. P.. (Year: 2011). Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome.Blood1184015–402321860019|
|Sorensen H. T.,Mellemkjaer L.,Olsen J. H.,Baron J. A.. (Year: 2000). Prognosis of cancers associated with venous thromboembolism.N. Engl. J. Med.3431846–185011117976|
|Sorensen H. T.,Mellemkjaer L.,Steffensen F. H.,Olsen J. H.,Nielsen G. L.. (Year: 1998). The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.N. Engl. J. Med.3381169–11739554856|
|Tian M.,Wan Y.,Tang J.,Li H.,Yu G.,Zhu J.,Ji S.,Guo H.,Zhang N.,Li W.,Gai J.,Wang L.,Dai L.,Liu D.,Lei L.,Zhu S.. (Year: 2011). Depletion of tissue factor suppresses hepatic metastasis and tumor growth in colorectal cancer via the downregulation of MMPs and the induction of autophagy and apoptosis.Cancer Biol. Ther.12896–90722052255|
|Tormoen G. W.,Cianchetti F.,Bock P.,McCarty O. J.. (Year: 2012). Development of coagulation factor probes for the identification of procoagulant circulating tumor cells.Front. Oncol. 2:110.10.3389/fonc.2012.00110|
|Tormoen G. W.,Rugonyi S.,Gruber A.,McCarty O. J.. (Year: 2011). The role of carrier number on the procoagulant activity of tissue factor in blood and plasma.Phys. Biol.8066005|
|Trousseau A.. (Year: 1865). “Phlegmasia alba dolens,” inClinique Medicale de l’Hotel-Dieu de Paris, ed.Trousseau A. (Paris: The New Sydenham Society) 654–712|
|Welsh J.,Smith J. D.,Yates K. R.,Greenman J.,Maraveyas A.,Madden L. A.. (Year: 2012). Tissue factor expression determines tumour cell coagulation kinetics.Int. J. Lab. Hematol.34396–40222348286|
|Xu C.,Gui Q.,Chen W.,Wu L.,Sun W.,Zhang N.,Xu Q.,Wang J.,Fu X.. (Year: 2011). Small interference RNA targeting tissue factor inhibits human lung adenocarcinoma growth in vitro and in vivo.J. Exp. Clin. Cancer Res.3063|
|Yates K. R.,Welsh J.,Echrish H. H.,Greenman J.,Maraveyas A.,Madden L. A.. (Year: 2011). Pancreatic cancer cell and microparticle procoagulant surface characterization: involvement of membrane-expres- sed tissue factor, phosphatidylser ine and phosphatidylethanolamine.Blood Coagul. Fibrinolysis22680–68721941170|
|Zacharski L. R.,Memoli V. A.,Rousseau S. M.. (Year: 1986). Coagulation-cancer interaction in situ in renal cell carcinoma.Blood68394–3992425868|
|Zacharski L. R.,Schned A. R.,Sorenson G. D.. (Year: 1983). Occurrence of fibrin and tissue factor antigen in human small cell carcinoma of the lung.Cancer Res.433963–39686305497|
Keywords: circulating tumor cells, thrombosis, tissue factor, metastasis, blood.
Previous Document: AZT as a telomerase inhibitor.
Next Document: Dying cell clearance and its impact on the outcome of tumor radiotherapy.